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Summary To assess the efficacy and toxicity of an outpatient combination chemotherapy in small-cell lung cancer (SCLC), we treated 70
consecutive patients with epirubicin 80 mg m-2 i.v. on day 1 and etoposide 200 mg o.d. p.o. on days 1-4 (EE) at 3-weekly intervals. The
median age of patients was 64 years (range 39-84). The male-female ratio was 42:28 and 35 (50%) had metastatic disease. Fifty-seven
patients were evaluable for response. The overall response rate was 64.4%, including 14 (23.7%) complete responses and 24 (40.7%) partial
responses. Median time to progression was 7 months in responders and 8 months in patients with limited disease. The median survival in
patients with limited disease was 10.5 months (range 0.5-70 +) and 7 months (range 0.5-24) in those with extensive disease. Improvement
of symptoms occurred in 79% of patients with shortness of breath, 80% with cough, 81% with haemoptysis and 68% with pain. In 19 patients
an increase in body weight was noted. Major (WHO grade 3/4) toxicities were neutropenia in 13 (18.5%) patients, alopecia in 33 (47.1%)
patients, mucositis in 15 (21.4%) patients, anorexia in eight patients (11.4%), nausea and vomiting in six patients (8.5%) and diarrhoea in 4
(5.7%) patients. In conclusion, EE is an active and well-tolerated outpatient regimen in the treatment of SCLC. The survival data in this
unselected group of patients were disappointing and the possible explanations for this are discussed.
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The standard therapy for patients with small-cell lung cancer
(SCLC) is combination chemotherapy (Hansen, 1992). It signifi-
cantly prolongs survival and can even cure a small number of
patients with limited disease. However, the majority of patients,
including those with limited disease, develop distant metastases
and die as a result oftheir disease (Albain et al, 1990).
No standard cytotoxic regimen exists for the treatment of
SCLC (Hansen, 1992). Various combinations have been tried, the
most long-standing being cyclophosphamide, doxorubicin and
vincristine (CAV). More recently, cisplatin with etoposide (PE)
has become a commonly used regimen (Loehrer, 1995), with
preliminary results suggesting an increased response rate in
limited disease when used with irradiation (Johnson et al, 1994).
The addition ofifosfamide resulted in the VIPregimen (etoposide,
ifosfamide and cisplatin), for which a survival advantage has been
claimed in extensive disease (Loehrer et al, 1995). More recently,
carboplatin has replaced cisplatin, with a similar response rate and
survival advantage being observed in patients with extensive
disease (Wolf et al, 1995). However, both these regimens require
inpatient administration ofup to 4 days, considerably adding to the
inconvenience to the patient and to the cost oftreatment.
Etoposide is a phase-specific drug, acting as a topoisomerase
inhibitor during late S phase or early G2 phase ofthe cell cycle. It
has been used as a single agent for first-line treatment in SCLC,
with a reported overall response rate in untreated patients of
35-85% (Pedersen and Hansen, 1983; Slevin et al, 1989).
Received20 September 1996
Revised 12 February 1997
Accepted 13 March 1997
Correspondence to: J Mansi, Consultant Medical Oncologist, Department of
Oncology, St George's Hospital, London SW17 OQT. Tel: 0181 725 2955;
Fax: 0181 725 2955
Prolonged administration was associated with significantly higher
complete and overall response rates, as well as improvement in
median survival time (Abratt et al, 1987; Slevin et al, 1989).
Epirubicin (4-epidoxorubicin), the stereoisomer of doxorubicin,
with less severe cardiotoxic effects than the parent compound, has
a recommended maximum cumulative dose twice that of doxoru-
bicin (Plosker and Faulds, 1993). Three trials have demonstrated
the activity ofepirubicin in SCLC (Blackstein etal, 1990; Eckhardt
et al, 1990; Macchiarini et al, 1990a). In the first two, previously
untreated patients with extensive disease were treated every 3 to 4
weeks at a dose of 100 mg m-2 and 120 mg m-2, and overall
response rates of 50% and 48% were reported respectively. In the
third trial patients with limited disease were also entered and an
overall response rate of33% was seen (Macchiarini et al, 1990a).
In the present study, we aimed to evaluate the activity of the
combination of epirubicin and oral etoposide with respect to its
toxicity profile, improvement in symptoms and effect on survival.
In addition, this particular regimen could be given in an outpatient
setting.
PATIENTS AND METHODS
From December 1989 to May 1995, 70 consecutive previously
untreated patients with a cytologically/histologically confirmed
diagnosis of SCLC were treated according to a standard protocol.
Patients received epirubicin 80 mg m-2 i.v. on day 1 and etoposide
200 mg orally o.d. on days 1-4 at 3-weekly intervals. Epirubicin
was administered by intravenous infusion over 30 min and etopo-
side as 50 mg capsules. This combination was given provided
there was adequate haematological (white blood cell count of
2 4000 ul-1, platelet count of 2 100 000g1-1), renal (serum creati-
nine < 1.5 mg dl-') and hepatic (total serum bilirubin < 2 mg dl-')
function. Those patients considered unfit for this treatment were
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given single-agent oral etoposide. Patients with a recent myocar-
dial infarction (within 3 months of SCLC diagnosis), congestive
heart failure, significant arrhythmia or uncontrolled infectious
disease were also excluded.
Drug doses were reduced to 75% in the event of neutropenic
sepsis or thrombocytopenia requiring transfusion. The treatment
was postponed for 1 or 2 weeks to allow recovery of haematol-
ogical function (white blood cell count 2 4000 p1-1 and platelet
count 2 100 000 p1-').
The following antiemetics were routinely administered with
chemotherapy: dexamethasone 8 mg i.v., metoclopramide 20 mg
i.v. with oral dexamethasone 2 mg t.d.s. for 3 days and oral
domperidone 20 mg q.d.s. for 5 days.
Therapy was repeated for a maximum of six cycles or until
progression. From late 1993, radiotherapy was offered to patients
with limited disease who achieved complete response (CR) or
partial response (PR) within three courses ofEE (40 Gy in 15 frac-
tions), in accordance with published data on the benefits ofadding
radiotherapy to chemotherapy in limited disease. Prophylactic
cranial irradiation was not given. Patients with brain metastases
received cranial irradiation. Palliative radiotherapy was adminis-
tered for symptom control as required.
PRETREATMENT EVALUATION AND FOLLOW-UP
Pretreatment evaluation consisted of complete history, physical
examination, full blood count andchemistry, urinalysis, chest radi-
ography or computerized tomography (CT) of the thorax, ultra-
sound of the liver, bone scan and bone radiographs (if bone scan
abnormal). A bronchoscopy was not required at diagnosis if this
had been established by other means. CT of the brain was only
performed in patients who had neurological symptoms. Limited
disease was defined as disease confined to the primary site,
mediastinum and unilateral supraclavicular nodes, according to
the Veterans' Administration Lung Cancer Study Group.
Patients underwent a clinical evaluation with full blood count,
biochemistry and chest radiography on day 1 of each cycle. All
other imaging, e.g. ultrasound or CT scan demonstrating
metastatic disease, was repeated after three and six courses of
cytotoxic therapy and if progressive disease was suspected.
Patients who completed therapy were monitored every 3 months
or more often as clinically indicated.
EVALUATION OF RESPONSE AND TOXICITY
Response
The efficacy of treatment was evaluated in terms of response,
duration of response and survival. Response criteria were those
defined by the WHO. Patients were assessable for response
provided they completed one or more courses of treatment. Time
to progression was calculated as the time from start of cytotoxic
therapy until definite progression or death. Survival was measured
from the firstday oftreatment to the date ofdeath (ofany cause) or
last follow-up.
Toxicity
The WHO criteria were used to report toxicity. All patients who
received atleast onedose were considered evaluable fortoxicity. The
toxicity isreported as the worstexperienced forallcycles perpatient.
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All patients were asked to assess the severity of their symptoms,
e.g. cough, haemoptysis, dyspnoea and chest pain, on a five-point
scale (0-4) on the first day oftreatment for each cycle. Any reduc-
tion in severity by 2 1 on this scale was taken as evidence ofsymp-
tomatic improvement.
Statisticalanalysis
Survival and duration of response curves were estimated by the
Kaplan-Meier method (Kaplan and Meier, 1958). In the survival
analysis, all causes of death were considered. All median values
are followed by range, and frequencies expressed in percentages
followed by 95% confidence intervals (CIs).
RESULTS
Response to treatment and survival
Patient characteristics are shown in Table 1. Median age was 64
years (range 39-84) and median performance status (PS) (WHO)
was 1 (range 0-3). Seventeen (24.2%) patients had a PS 2, and a
total of 40 (57.1%) patients were hyponatraemic and/or had a
raised lactate dehydrogenase (LDH). Thus, a total of 13 (37.1%)
patients with limited disease and 20 (57.1%) patients with exten-
sive disease had poor prognostic features.
Of the 70 patients treated with the EE combination, 59 were
evaluable for response. Eleven were not assessable for response to
chemotherapy for the following reasons: five patients died before
the second cycle ofchemotherapy; two died ofneutropenic sepsis;
and three suffered unexplained deaths. Two patients developed
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prolonged infective complications after recovery from neutropenia
in the first cycle precluding furtherchemotherapy. Ofthe remaining
excluded patients, two had fatal gastrointestinal bleeds, one had a
cerebrovascular event and one was lost to follow-up. Two patients
progressed after the first treatment and are included in the analysis.
The overall response rate was 64.4% (CI 52-76.8%). Fourteen
patients (23.7%, CI 12.7-34.7%) had a complete remission, 24
(40.7%, CI 28-53.4%) a partial remission, eight stable disease and
13 progressed on treatment. In patients with limited disease, 24 had
an objective response (77.4%, CI 62.4-92.4%), including ten
(32.25%, CI 15.46-49.04%) complete responses. Four (14.2%, CI
1.1-27.3%) patients with extensive disease had acomplete response.
Median time to progression for all responders was 7 months
(range 1-70 +). The median time to progression was 8 months for
patients with limited disease (range 1-70 +) and 5.75 months
(range 1-16) for patients with extensive disease. The median
survival was 10.5 months (range 0.5-70 +) in patients with limited
disease and 7 months (range 0.5-24) for those with extensive
disease. There was a statistically significant difference in survival
between patients with limited disease and those with metastatic
disease (P = 0.02).
Eleven patients (31.4%) with limited disease survived 12 months
or more, and two (5.7%) survived more than 24 months, with one
long-term ongoing survivor at 70 months. Only six patients
(17.1%) with extensive disease survived 12 months or more.
Symptomatic improvement
An improvement of symptoms occurred in 79% (CI 68.3-89.7%)
of patients with shortness of breath, 80% (CI 69.5-90.5%) with
cough, 81% (CI 71.5-92.1%) with haemoptysis and 68% (CI
55.7-80.3%) with pain. In a total of 19 of the 40 patients who
presented with weight loss, an increase in body weight was noted
at completion of treatment.
Toxicity
Eleven patients were hospitalized for neutropenic sepsis. WHO
grade 3 and 4 haematological toxicity was as follows: neutropenia
was observed in 13 (18.5%) patients; thrombocytopenia requiring
platelet transfusion in two (2.8%) patients; and anaemia in three
(4.2%) patients.
Two toxic deaths were documented. Both patients died with
sepsis while neutropenic.
A 25% dose reduction of both epirubicin and etoposide was
necessary in 18 patients. This included ten patients with
neutropenic infection, two patients with thrombocytopenia, four
patients with mucositis, one patient with diarrhoea and one patient
because of age. Three patients had a 25% dose reduction of
epirubicin alone; two with abnormal liver function tests but
normal bilirubin and one with ischaemic heart disease.
Chemotherapy was delayed in three patients because of low
blood count; in one patient because of diarrhoea and in eight
patients to allow recovery from neutropenic infection.
Alopecia was almost universal. Grade 3 or 4 mucositis,
anorexia, nausea and vomiting and diarrhoea was seen in 21.4%,
11.4%, 8.5% and 5.7% patients respectively.
Radiotherapy
Eight patients with limited disease who responded to
chemotherapy received thoracic irradiation whereas 16 did not.
Radiotherapy to the chest was also given to four patients as pallia-
tion and to four at the time ofrelapse. Cranial irradiation was given
for palliation ofcerebral metastases in 13 patients.
DISCUSSION
Although SCLC is highly sensitive to both chemotherapy and
radiotherapy, the majority of patients are destined to die of
progressive disease. Many different chemotherapy regimens have
been evaluated but no major advances have resulted from autolo-
gous bone marrow transplantation, the use of granulocyte colony-
stimulating factor (G-CSF) to escalate the doses or to increase the
dose frequency, or by novel combinations of existing drugs
(Klastersky, 1995). Until such time as new drugs and drug combi-
nations have been identified that enhance both response rates and
survival durations, treatment should be with a regimen that
combines efficacy with patient acceptability, low toxicity and cost.
The combination of epirubicin and etoposide has been tested in
several phase II trials but always in addition to other drugs, such as
cyclophosphamide (Macchiarini et al, 1990b), cisplatin (Rosell et
al, 1992), ifosfamide (Sculier et al, 1995) or in four drug regimens
(Bamberga et al, 1992).
Variable doses ofanthracycline, either doxorubicin (45 mg m-2)
or epirubicin (60 mg m-2 or 90 mg m-2), given on day 1 with ifos-
famide (1.5 g m-2) and etoposide (80 mg m-2) day 1-3, resulted in
response rates varying from 73% to 83% (Sculier et al, 1995). The
overall median survival was 42 weeks, which is very similar to our
own results. Higher doses of epirubicin (100-120 mg m-2) given
on day 1 with cisplatin (70 mg m-2) and etoposide (60-80 mg m-2)
for days 1-5 had a higher response rate at 81% and median
survival of 13 months (Rosell et al, 1992). However, this was at the
expense ofincreased toxicity with 53% neutropenic fever and 40%
stomatitis compared with 15% grade 3 and 4 infection and 3%
stomatitis in the ifosfamide-containing combination. Our own
toxicity data showed the two-drug regimen to have a 15.7% rate of
neutropenic sepsis and 21.4% for stomatitis. The planned epiru-
bicin dose intensity up to 120 mg m-2, which was approximately
30% higher than that used by both Sculier and ourselves, may well
explain both the increased activity seen with this regimen as well
as the marked toxicity.
Unfortunately, even though both epirubicin and etoposide are
active single agents for SCLC, our response and survival data may
be compromised as many of our patients had poor prognostic
features such as hyponatraemia (11 patients), elevated LDH (29
patients) and syndrome of inappropriate antidiuretic hormone
(three patients). Poor performance status (PS 3) patients were also
included and not all the patients with limited disease received
thoracic irradiation, which has subsequently been demonstrated to
add to the benefit of chemotherapy. The value of thoracic irradia-
tion in patients with limited disease was uncertain at the time this
protocol was initiated.
The addition ofa third drug or combining etoposide with a plat-
inum compound might have been beneficial. The combination of
carboplatin with oral etoposide gave an overall response rate of
67%, with a complete response of21% in 106 patients (Pfeiffer et
al, 1995). These results are similar to our own (overall response
rate 66.6% and complete response 24.5%). Their response rate in
patients with limited disease was higher (89% with CR 41%) than
ours (77.4% with CR 32%) and the median survival at 15 months
was comparable to that obtained in trials in which both the
carboplatin and etoposide were administered intravenously.
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Myelosuppression was the main toxicity, with grade 3 or 4
leucopenia observed in 20% of patients and thrombocytopenia in
16% ofpatients. In afurther study, acombination oforal etoposide
100 mg m-2 for 7 days and carboplatin 150 mg m-2 i.v. on day 1
was given to 47 elderly (> 45 years) or medically unfit patients
with SCLC (Evans et al, 1995). Of the 38 patients evaluable for
response, 71% responded with a complete response in 29% of
patients. The median survival was 46 weeks and the treatment was
generally well tolerated, with the majortoxicity being neutropenia.
Both these studies and our study show that oral etoposide can be
incorporated in regimens for SCLC administered on an outpatient
basis that are effective and well tolerated.
The relatively poor results in terms of survival in our study
would imply that our regimen has less activity than a
platinum-etoposide combination. It is not clear why this should
be. It is perhaps accentuated by reporting the results ofunselected
patients compared with highly selected patients in phase JI/T
studies. Interestingly, a very short median survival of only 20
weeks was seen in an MRC study comparing ECMV (etoposide,
cyclophosphamide, methotrexate and vincristine) with EV (etopo-
side and vincristine) (Bleehen et al, 1996). This was in part
thought to be related to patients ofpoorperformance status as well
as a high proportion (17%) ofearly deaths, which may have been
due to undiagnosed sepsis. Our own early death rate was lower at
10%, butwas still a significantproportion. In addition, theefficacy
of oral etoposide as a single agent has recently been questioned
(Thatcher et al, 1996; MRC Lung Cancer Working Party, 1996).
A multicentre randomized trial of oral etoposide compared with
standard intravenous multidrug chemotherapy was stopped owing
to poor response rates of45% vs 51% respectively.
In view of the poor duration of survival we reported with oral
etoposide and epirubicin, we have decided to consider a platinum-
based regimen in future.
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